Mycoplasma pneumonia (MP), called as M.pneumonia, which causes respiratory infection that opens out easily by coming in contact with respiratory fluids causing Mycoplasma pneumonia. It is also known as walking pneumonia as this kind of bacteria may spread very easily in the public areas. Mycoplasma pneumonia bacteria are contagious in nature, they can easily get transmitted through air, which may affect healthy person. In recent times, Mycoplasma diagnostics is been observed as a rapidly progressing and rising area in the in-vitro diagnostic industry. For the earlier stage diagnosis of MP, the specialist uses stethoscope to notice the undesirable sounds in person’s chest. For further diagnosis, medical practitioner perform chest X-ray, CT scan or blood test for detection of infection.

Therapists and researchers are expecting the global Mycoplasma Diagnostics Market to be more ambitious, fast growing and dynamic. According to World Health Organization (WHO), which is concerned with the international public health, there are nearly 600 diagnosis centers and around 200 Independent working laboratories to reach mycoplasma diagnosis in the United States. Moreover, in Austria there are public funding agenesis, such as Austrian Research Promotion agency to (FFG) which invests partly in R&D for MP Diagnosis.

Increased lung and respiratory disease to be major market driver for Mycoplasma Diagnostics

Increasing incidents of respiratory tract infections globally, doors are opened for mycoplasma diagnostics market and with advancements, key players of mycoplasma diagnostics devices are expecting the increase in demand for better diagnosis towards non-pulmonary treatments which would lead the global market on in nearby future. According to the Forum of International Respiratory Society 2014, number of deaths due to respiratory diseases, pulmonary sickness and tuberculosis has been increased and these numbers are expected to increase in upcoming years, which is expected to boost growth of mycoplasma diagnostic market.

One of the major factor contributing the growth for mycoplasma diagnostics market is increasing geriatric population with respiratory disease. According to the World Health Organizations (WHO), 34.3% of the geriatric population was suffering majorly from respiratory tract infection and lung cancer. In-order to overcome the chronic respiratory disorders, effective mycoplasma diagnosis is essential, which would eventually boost the mycoplasma diagnostics market globally.

Lack of awareness towards Mycoplasma Diagnostics devices restraining the growth of mycoplasma diagnostics device market.

Mycoplasma diagnostic device market is increasing globally. However, mycoplasma diagnostics market may face undesirable challenges. Lack of awareness in people for the advantages of the diagnosis is the main misleading reason to restrain the growth. Moreover, cost is another disadvantage to lose the demand and need for Mycoplasma Diagnosis devices.

Raising needs for better techniques in Mycoplasma Diagnostics market industry to be major market driver.

According to WHO 2016, the advance techniques such as Polymerase Chain Reaction (PCR), DNA staining and Immunoassay have dominated the market. However, remarkable growth is observed in use of techniques, such as ELISA and RIA. These techniques are cost effective and they are used in pharmaceutical and diagnostic industries, due to their ease of use and availability.

Mycoplasma Diagnostics Market-Regional Analysis

On the basis of regions the mycoplasma diagnostics market is segmented as, the North America, Europe, Middle East Africa, Asia Pacific and Latin America

According to the World Health Organization (WHO) 2015, the North America holds 35.6% share of markets leading overall global marketing for Mycoplasma diagnostics. However, according to WHO 2016, around 7.4 million people were reported to have mycoplasma disease in Asia pacific region, which is expected to increase in upcoming future. Profitable opportunities in Mycoplasma Diagnostics Market in Asia Pacific region are expected, due to increasing number of respiratory tract infection as well as the increasing mortality rate. Key players along with Government of this region is expecting more opportunities in Asia Pacific regions leading the global market in upcoming years.

Mycoplasma Diagnostics Device Market-Competitive landscape

The major key players in the global mycoplasma diagnostics market industry are: Agilent Technologies, American Type Culture Collection (ATCC), Thermo Fisher Scientific, Takara Holding, PromoCell GmbH, Merck KGaA, Lonza Group, Savyon Diagnostics, Tecan Group, Charles River Laboratories International, F Hoffmann-La Roche and Sartorius Stedim BioOutsource. Major role players in the global mycoplasma diagnostic industries, such as Thermo Fishers Scientifics and Merck KGaA holds around 23% share in the global market, which increases the opportunities towards the profitable and global market insights in Mycoplasma Diagnostics.

Key Development

In May 2019, QIAGEN, launched QIAstat-Dx syndromic testing after receiving 510(k) clearance by the U.S. Food and Drug Administration, QIAstat-Dx Respiratory Panel for simultaneous qualitative detection and identification of multiple respiratory viral and bacterial pathogens.
In July 2018, ATCC, launched its new PCR-based service to detect mycoplasma contamination in cell cultures. This growing service portfolio is part of a larger effort by ATCC to support the authentication of cell lines used in basic and translational research and complements the STR Profiling Service.
In 2018, Konica Minolta, Inc., launched Konica Minolta Precision Medicine Japan, Inc., is a 100%-owned subsidiary of Konica Minolta with responsibility for marketing high-end precision medicine tools and diagnostic services in Japan. Precision medicine is medical care that uses genetic and molecular profiling to optimize treatment for specific groups of patients.
In 2016, GENESIS, launched mycoplasma pneumonia antigen rapid diagnostic test kit, this kit detects the antigen of P1 gene of M. pneumonia from the specimen collected from the suspicious patients infected by M. pneumonia.
In 2015, Merck acquired Sigma-Aldrich Co., one of the global leaders in life science sector to expand its product offering and through this acquisition company offers product into mycoplasma diagnostics device market

Mycoplasma Diagnostics Device Market-Taxonomy

The global Mycoplasma Diagnostics device market is segmented on the basis of techniques, end users and regions

By Techniques

Polymerase Chain Reaction (PCR)
Immunoassay
- ELISA (Enzyme linked immune sorbant assay)
- RIA (Radio immuno assay)
Microbial culture techniques
DNA staining

By End User